Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo

Garyfallia Psarrakou; Michael Chatzistefanou; Panagiotis Efentakis; Aimilia Varela; Eleni‐Dimitra Papanagnou; Panagiota Nikolaou; Maria Tsoumani; Constantinos H. Davos; Efstathios Kastritis; Ioannis P. Trougakos; Meletios A Dimopoulos; Evangelos Terpos; Ioanna Andreadou

doi:10.1093/ehjci/ehaa946.3400

Abstract

2 min read

Abstract Background Carfilzomib (Cfz) is an irreversible proteasome inhibitor, indicated for the treatment of Multiple Myeloma (MM); however, is associated with cardiotoxicity in humans. Metformin (Met) has been suggested as a prophylactic therapy against Cfz-induced cardiotoxicity in mice. Purpose Considering that MM is an elderly disease, manifested in presence of cardiovascular comorbidities, we investigated the cardioprotective effect of Met against Cfz-cardiomyopathy on the age- or hyperlipidaemia-burdened myocardium in vivo. Methods Aging model: Male C57BL/6 mice, 15-month old, were randomized into: 1. Control (N/S 0.9%), 2. Met (140 mg/kg, po), 3. Cfz (8mg/kg, ip) and 4. Cfz+Met (8 and 140 mg/kg respectively) (n=5–7/group). Hyperlipidaemic model: ApoE−/− male mice, 20-weeks old were randomized into: 1. Control (N/S 0.9%), 2. Met (140 mg/kg, po), 3. Cfz (8mg/kg, ip) and 4. Cfz+Met (8 and 140 mg/kg respectively) (n=6/group). Cfz was administered every 48 hours and Met every 24 hours for 6 days. At baseline and at the end of treatments mice underwent echocardiography. Proteasomal activity and molecular signaling mechanisms were assessed in myocardial tissue and in peripheral blood mononuclear cells (PBMCs). Results Aging model: Proteasome activity was significantly reduced in myocardial tissue of aged vs young mice (P&lt;0.05). Cfz-treated mice showed an additional decrease in proteasomal activity compared to Control (P&lt;0.05) and Met (P&lt;0.01) groups, in heart and PBMCs. A significant fractional shortening (FS%) reduction was observed in Cfz group vs controls at day 6 (29.90±1.7 vs 37.60±0.2, respectively, P&lt;0.05) while Met in both Met and Cfz+Met groups maintained FS% vs controls (34.88±1.6, 33.20±0.6 vs 37.60±0.2, respectively, P=NS). By investigating molecular signaling pathways involved in cardioprotection, we observed that Cfz led to a decrease of Akt and AMPKα phosphorylation (P&lt;0.05 vs Control), whereas Cfz+Met co-administration restored Akt and AMPKα phosphorylation and upregulated t-eNOS and t-Akt (P&lt;0.05 vs Control). Hyperlipidaemic model: In ApoE−/− mice, no significant reduction of myocardial proteasomal activity was observed, whilst PBMCs proteasomal activity was decreased compared to controls (P&lt;0.05). Cfz treated ApoE−/− mice exhibited a reduction of myocardial (P&lt;0.01 in Cfz and P&lt;0.001 in Cfz+Met) and PBMCs' proteasome activity (P&lt;0.001) vs controls. Interestingly, Cfz, Met as well as the combination led to a decrease in FS% versus controls (44.00±1.2, 42.33±0.92, 42.33±1.0 vs 47.50±0.72 respectively, P&lt;0.05). Conclusions Our results demonstrate that Met retains its prophylactic potency against Cfz-induced cardiotoxicity in aged mice and activates cardioprotective signaling molecules. In the ApoE−/− mice, Met failed to exert cardioprotection against Cfz induced cardiomyopathy. Therefore, the monitoring of the cardiovascular burden seems to be of outmost importance in managing Cfz cardiac adverse effects. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Amgen

Related publications

Article2020

Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging

Panagiotis Efentakis, Garyfallia Psarrakou, Panagiota Nikolaou, Michael Chatzistefanou, Eleni‐Dimitra Papanagnou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2018

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos

Article2018

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

Panagiotis Efentakis, Georgios Kremastiotis, Aimilia Varela, Panagiota Nikolaou, Eleni‐Dimitra Papanagnou, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Efstathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioannis P. Trougakos, Ioanna Andreadou, Evangelos Terpos

Article2019

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, Ioanna Andreadou, Panagiota Nikolaou, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, Meletios A Dimopoulos, Evangelos Terpos

Article2017

Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Eleni‐Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Evangelia Chavdoula, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, Ioanna Andreadou, Evangelos Terpos